Trials / Completed
CompletedNCT06550271
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 67 (actual)
- Sponsor
- AgelessRx · Industry
- Sex
- All
- Age
- 40 Years – 120 Years
- Healthy volunteers
- Accepted
Summary
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rapamycin | Rapamycin in 2 different dosage forms (compounded and generic) |
Timeline
- Start date
- 2023-04-25
- Primary completion
- 2023-12-15
- Completion
- 2023-12-15
- First posted
- 2024-08-13
- Last updated
- 2024-08-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06550271. Inclusion in this directory is not an endorsement.